Maze Therapeutics, Inc. MAZE
26.05
(0.16)
(0.61%)
as of 25 Sep
- Market cap
- $1.5B
- P/E
- 0.0×
Follow MAZE
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (37.35%) | (38.67%) | (598.95%) | (5,050.31%) |
+8 more TTM periods Free account |
|
| (31.99%) | (32.57%) | (41.12%) | (66.86%) | ||
ROIC |
(112.36%) | (297.61%) | (684.43%) | 0.00% | |
Return on Tangible Assets |
(33.24%) | (33.74%) | (39.47%) | (37.65%) | |
Average Days of Receivables |
— | 0.00 | — | — | |
Free Cash Flow per Share |
(1.81) | (2.27) | (2.62) | (2.36) | |
Free Cash Flow |
(106.84) | (122.12) | (112.73) | (108.03) | |
Capital Expenditures |
(0.30) | (0.59) | (0.79) | (1.36) | |
Piotroski F-Score |
3.00 | 3.00 | 3.00 | 1.00 | |
| Other line items | |||||
Cash ROIC |
(11.80%) | (16.58%) | (16.06%) | (13.97%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.80 | 0.99 | 0.85 | 0.76 | |
Depreciation/Fixed assets |
0.55 | 0.54 | 0.48 | 0.47 | |
Capex/Depreciation |
(0.13) | (0.23) | (0.33) | (0.52) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.81) | (2.25) | (2.60) | (2.33) | |
Capex per Share |
(0.01) | (0.01) | (0.02) | (0.03) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates